Antibacterial Resistance Leadership Group (ARLG) begins clinical trial of phage therapy for cystic fibrosis
The trial is evaluating whether the bacteriophage, or “phage,” therapy is safe and able to reduce the amount of bacteria in the lungs of volunteers
The Antibacterial Resistance Leadership Group (ARLG) has begun a clinical trial of phage therapy for cystic fibrosis in adults who carry Pseudomonas aeruginosa (P. aeruginosa) in their lungs, according to a statement from the National Institute of Health (NIH).
The trial is evaluating whether the bacteriophage, or “phage,” therapy is safe and able to reduce the amount of bacteria in the lungs of volunteers. Investigators aim to enroll up to 72 adults at 16 CF centres across the US, the statement said.
It also said that phages are viruses that can kill or neutralise specific bacteria while leaving non-target bacteria and human cells unharmed. For more than a century, researchers have considered the potential use of phages as therapeutics, theorising that mixtures of bacteriophages might be used on their own, or in conjunction with antibiotics, to treat bacterial infections—especially those resistant to antibiotics.
P. aeruginosa, a serious and sometimes deadly bacterium frequently acquired in healthcare settings, is the most common bacterial cause of CF exacerbations. It can take advantage of the tissue damage caused by CF changes in mucus to infect and colonise the lungs. Multidrug-resistant P. aeruginosa infections are becoming increasingly common, and, in recent years, only a handful of new antibiotics have been approved to treat them.
“The prevalence of antibiotic resistance is concerning, and the need for more effective therapeutics for vulnerable populations, such as people with cystic fibrosis, is especially urgent. Although research on bacteriophage therapy may still be in its infancy in the United States, we hope that this study, and others like it, could open the doors to a new type of therapy for difficult-to-treat bacterial infections,” Anthony S Fauci, Director, NIAID, MD, in the statement.
It further informed that the experimental phage therapeutic, WRAIR-PAM-CF1, is manufactured by Adaptive Phage Therapeutics, Gaithersburg, Maryland. It contains a cocktail of four bacteriophage species that naturally infect P. aeruginosa and take over its cellular processes, killing the bacterium in the process. The phages in the cocktail are highly specific, and do not attack human cells. They have been cultivated, purified, and extensively studied in a lab setting. Genetic analyses of these phages have determined that they do not carry harmful genes that could accidentally be transferred to the bacteria they infect, such as genes that could confer antibiotic resistance.
The trial will enroll CF patients who chronically harbor P. aeruginosa in their respiratory tracts. Participants will receive the phage cocktail as a single IV infusion at one of three dosage levels. Researchers will gather data on safety and microbiological activity; how the phages function in the body; how the cocktail affects the participants’ lung function; whether the therapy works differently on P. aeruginosa from different geographical regions; and whether the therapy changes participants’ overall quality of life, the statement added.
The trial will begin as a phase -Ib trial, and will expand to a phase-II trial. First, two participants per dosage level will receive an unblinded infusion of the therapeutic and will be closely monitored for four days, thereafter. If no serious safety issues are identified, researchers will begin enrolling additional participants, who will be randomly assigned to receive a single infusion of the therapeutic at one of the three dosage levels, or a placebo infusion. This part of the trial will be double-blinded. So, neither the participants nor the investigators will know who is receiving placebo. An assessment of the therapeutic’s safety and microbiological impact will be conducted after eight participants have completed each dosage. The results of this assessment will determine which dosage will be given in the next stage of the trial. The phase-II trial will enroll up to 50 participants who will be randomly assigned to receive the selected dose of the phage cocktail or a placebo. Each volunteer will make multiple follow-up visits to monitor their health and reaction to the experimental therapeutic, concluded the statement.